Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis
This study underscores the importance of tissue tofacitinib levels in UC treatment efficacy, with pSTAT3 reduction serving as a potential marker of drug efficacy. RNA sequencing identified molecular pathways for potential biomarkers and novel therapeutic targets in tofacitinib non-responders.
Authors
- Jack Stylli
- Sara van Gennep (ORCID: https://orcid.org/0000-0002-9843-0134)
- Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
- Pejman Rahimian (ORCID: https://orcid.org/0000-0003-0349-7190)
- Marc Ferrante (ORCID: https://orcid.org/0000-0003-1492-0716)
- Ariella Kelman
- Dahham Alsoud (ORCID: https://orcid.org/0000-0002-6795-6328)
- Bram Verstockt (ORCID: https://orcid.org/0000-0003-3898-7093)
- Jeff Smith (ORCID: https://orcid.org/0000-0002-3265-7184)
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Joep van Oostrom
- Sujay Singh (ORCID: https://orcid.org/0009-0008-1039-0870)
- João Sabino (ORCID: https://orcid.org/0000-0002-8892-7075)
- Sharat Singh (ORCID: https://orcid.org/0000-0001-8707-4317)
- Sare Verstockt (ORCID: https://orcid.org/0000-0001-6222-8527)
Institutions
- Mirati Therapeutics (United States) (US)
- Amsterdam Neuroscience (NL)
- Cidara Therapeutics (United States) (US)
- Amsterdam University Medical Centers (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf063
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Universiteit van Amsterdam
- Fonds Wetenschappelijk Onderzoek
- KU Leuven
- Vlaamse regering